WO2002064134A3 - Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2 - Google Patents

Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2 Download PDF

Info

Publication number
WO2002064134A3
WO2002064134A3 PCT/FR2002/000490 FR0200490W WO02064134A3 WO 2002064134 A3 WO2002064134 A3 WO 2002064134A3 FR 0200490 W FR0200490 W FR 0200490W WO 02064134 A3 WO02064134 A3 WO 02064134A3
Authority
WO
WIPO (PCT)
Prior art keywords
indomethacin
calcium
treatment
oxygenase
cyclo
Prior art date
Application number
PCT/FR2002/000490
Other languages
English (en)
Other versions
WO2002064134A2 (fr
WO2002064134A8 (fr
Inventor
Abderrahim Bennis
Jean-Jacques Serrano
Farid Bennis
Original Assignee
Laprophan Laboratoires De Prod
Abderrahim Bennis
Jean-Jacques Serrano
Farid Bennis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laprophan Laboratoires De Prod, Abderrahim Bennis, Jean-Jacques Serrano, Farid Bennis filed Critical Laprophan Laboratoires De Prod
Publication of WO2002064134A2 publication Critical patent/WO2002064134A2/fr
Publication of WO2002064134A3 publication Critical patent/WO2002064134A3/fr
Publication of WO2002064134A8 publication Critical patent/WO2002064134A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet l'utilisation de l'indométacine calcique, notamment pehtahydratée, pour l'obtention d'un médicament destiné à traiter, de façon prophylactique ou curative, les pathologues à médiation de la cyclooxygénase 2.
PCT/FR2002/000490 2001-02-09 2002-02-08 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2 WO2002064134A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0101772 2001-02-09
FR0101772A FR2820636B1 (fr) 2001-02-09 2001-02-09 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Publications (3)

Publication Number Publication Date
WO2002064134A2 WO2002064134A2 (fr) 2002-08-22
WO2002064134A3 true WO2002064134A3 (fr) 2003-10-16
WO2002064134A8 WO2002064134A8 (fr) 2004-04-29

Family

ID=8859826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000490 WO2002064134A2 (fr) 2001-02-09 2002-02-08 Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2

Country Status (2)

Country Link
FR (1) FR2820636B1 (fr)
WO (1) WO2002064134A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US7790706B2 (en) 2002-06-14 2010-09-07 The University Of Edinburgh Treatment of inflammation with 5α reduced metabolites
EP1396547A1 (fr) * 2002-09-05 2004-03-10 Universitair Medisch Centrum Utrecht Métabolites d'acide arachidonique et modulation de la mitose et de l'apoptose de cellules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856511A1 (fr) * 1997-01-29 1998-08-05 Laprophan (Laboratoires de Produits Pharmaceutiques d'Afrique du Nord) Indométacine calcique pentahydratée et sa préparation
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6046231A (en) * 1998-05-15 2000-04-04 The Board Of Trustees Of The University Of Illinois Use of 4'-bromoflavone in a cancer chemopreventative composition and method
WO2000038716A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Therapie combinant la radiotherapie et un inhibiteur de la cyclooxygenase-2 permettant de traiter les maladies neoplasiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856511A1 (fr) * 1997-01-29 1998-08-05 Laprophan (Laboratoires de Produits Pharmaceutiques d'Afrique du Nord) Indométacine calcique pentahydratée et sa préparation
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6046231A (en) * 1998-05-15 2000-04-04 The Board Of Trustees Of The University Of Illinois Use of 4'-bromoflavone in a cancer chemopreventative composition and method
WO2000038716A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Therapie combinant la radiotherapie et un inhibiteur de la cyclooxygenase-2 permettant de traiter les maladies neoplasiques

Also Published As

Publication number Publication date
FR2820636B1 (fr) 2007-10-05
WO2002064134A2 (fr) 2002-08-22
FR2820636A1 (fr) 2002-08-16
WO2002064134A8 (fr) 2004-04-29

Similar Documents

Publication Publication Date Title
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
MXPA03002814A (es) Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias.
ZA200306806B (en) Preparation for the prophylaxis of restenosis.
ZA200309977B (en) Arylamines for the treatment of conditions associated with GSK-3.
HK1068778A1 (en) Insert for the treatment of dry eye
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
HK1061021A1 (en) Pyrazole derivatives for the treatment of viral diseases.
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
ZA200307102B (en) The use of enmantiomeric pure escitalopram.
AU2003219100A1 (en) Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
ZA200003236B (en) Combination therapy for the treatment of migraine.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
WO2002060483A3 (fr) Perylenequinones utilisees comme photosensibilisants et sonosensibilisants
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2002064134A8 (fr) Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
AU2001285156A1 (en) Combination therapy for the treatment of migraine
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
AU2002237368A1 (en) Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
ZA200002343B (en) Combination therapy for the treatment of migraine.
HK1056828A1 (en) Treatment of burns.
AUPQ741500A0 (en) C.m. body healer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 34/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP